Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
The latest update is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma AB has announced its Annual General Meeting scheduled for June 25, 2025, in Lund, Sweden. The meeting will cover various agenda items including the presentation of financial statements, election of board members, and proposals for a long-term incentive program. This meeting is crucial for stakeholders as it will address key corporate governance issues and strategic decisions that could impact the company’s future direction and market positioning.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a biotechnology company based in Lund, Sweden, specializing in the development of innovative immunomodulatory treatments. The company focuses on addressing rare immunological diseases and conditions, aiming to provide transformative therapies for patients with unmet medical needs.
Average Trading Volume: 172,057
Current Market Cap: SEK1.62B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.